Literature DB >> 3069254

The antibody spectrum in individuals with defect expression of HLA class II and the LFA-1 glycoprotein family genes.

C I Smith1, C Bremard-Oury, F Le Deist, C Griscelli, P Aucouturier, G Möller, L Hammarström, J L Preud'homme, R S Weening.   

Abstract

HLA class II antigens and the LFA-1 (lymphocyte function-associated type 1) glycoprotein family are cell surface structures of central importance in many lymphocyte reactions. Specific antibodies are normally restricted to particular IgG subclasses. In order to study the mechanism of isotype restriction we have analysed specific IgG1, IgG2, IgG3 and IgG4 antibodies directed against a number of different protein and polysaccharide antigens in individuals with HLA class II or LFA-1 deficiency. HLA class II deficiency resulted in decreased total IgG2, IgG4 and IgA in 4/4 patients, whereas total IgM and IgG were low in 2/4. In HLA class II deficiency the levels of specific antibodies directed against protein as well as polysaccharide antigens were frequently low. Virtually normal total as well as specific antibody levels were found in individuals with both severe and moderate forms of LFA-1 deficiency. There was no clear evidence for an abnormal subclass pattern of specific antibodies with a shift from one subclass to an isotype which is normally not used, in any of the patient groups investigated.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3069254      PMCID: PMC1542022     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  13 in total

Review 1.  Thymus-independent B-cell induction and paralysis.

Authors:  A Coutinho; G Möller
Journal:  Adv Immunol       Date:  1975       Impact factor: 3.543

2.  IgG subclass levels in infancy and childhood.

Authors:  V A Oxelius
Journal:  Acta Paediatr Scand       Date:  1979-01

3.  Cloning of cDNA encoding the murine IgG1 induction factor by a novel strategy using SP6 promoter.

Authors:  Y Noma; P Sideras; T Naito; S Bergstedt-Lindquist; C Azuma; E Severinson; T Tanabe; T Kinashi; F Matsuda; Y Yaoita
Journal:  Nature       Date:  1986 Feb 20-26       Impact factor: 49.962

4.  IgG subclass distribution of antibodies against S. aureus teichoic acid and alpha-toxin in normal and immunodeficient donors.

Authors:  L Hammarström; M Granström; V Oxelius; M A Persson; C I Smith
Journal:  Clin Exp Immunol       Date:  1984-03       Impact factor: 4.330

5.  Distribution of IgG subclass levels in normal adult sera as determined by a competitive enzyme immunoassay using monoclonal antibodies.

Authors:  P Aucouturier; S Mounir; J L Preud'homme
Journal:  Diagn Immunol       Date:  1985

6.  Clinical and laboratory features of patients with an inherited deficiency of neutrophil membrane complement receptor type 3 (CR3) and the related membrane antigens LFA-1 and p150,95.

Authors:  G D Ross
Journal:  J Clin Immunol       Date:  1986-03       Impact factor: 8.317

7.  Plasma anti-pneumococcal antibody activity of the IgG class and subclasses in otitis prone children.

Authors:  A Freijd; L Hammarström; M A Persson; C I Smith
Journal:  Clin Exp Immunol       Date:  1984-05       Impact factor: 4.330

8.  Bone-marrow transplantation for inborn error of phagocytic cells associated with defective adherence, chemotaxis, and oxidative response during opsonised particle phagocytosis.

Authors:  A Fischer; P H Trung; B Descamps-Latscha; B Lisowska-Grospierre; I Gerota; N Perez; C Scheinmetzler; A Durandy; J L Virelizier; C Griscelli
Journal:  Lancet       Date:  1983-08-27       Impact factor: 79.321

9.  Immunologic studies with LFA-1- and Mo1-deficient lymphocytes from a patient with recurrent bacterial infections.

Authors:  F Miedema; P A Tetteroo; F G Terpstra; G Keizer; M Roos; R S Weening; C M Weemaes; D Roos; C J Melief
Journal:  J Immunol       Date:  1985-05       Impact factor: 5.422

Review 10.  B-cell stimulatory factor-1/interleukin 4.

Authors:  W E Paul; J Ohara
Journal:  Annu Rev Immunol       Date:  1987       Impact factor: 28.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.